In AD patients’ brains, the amyloidogenic pathway is significantly enhanced and AβPP undergoes cleavage by β- and γ-secretases, releasing soluble sAβPPβ and Aβ peptides (mainly Aβ40 and Aβ42). Here, APP is linked to Alzheimer disease.